Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment undergoing clinically indicated contrast enhanced multidetector computed tomography (MDCT). Serum creatinine will be measured before and up to 48-72 hours post dose.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bracco Diagnostics, Inc

Criteria

Inclusion Criteria:

• Referred for contrast enhanced MDCT

• Documented predose eGFR of greater than or equal to 20 and less than 60 mL/min/1.73m2

• Diagnosed as having diabetes mellitus

Exclusion Criteria:

• Unstable renal function

• Unstable diabetes

• Concurrent administration of nephrotoxic drugs

• Undergoing dialysis